U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx DTC Print and Digital Ads - Brief Summary of Risks
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
What is FDA Rx DTC Print and Digital Ads - Brief Summary of Risks?
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form. Apply to print, digital display and sponsored image ads that name a prescription drug and its use.
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
How can marketing teams comply?
Apply to print, digital display and sponsored image ads that name a prescription drug and its use.
What is FDA Rx DTC Print and Digital Ads - Brief Summary of Risks?
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, patients · Prescription Drug · pharma
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Request a free compliance scan of your homepage and book a time with Warrant.